<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802672</url>
  </required_header>
  <id_info>
    <org_study_id>CPL-302</org_study_id>
    <nct_id>NCT00802672</nct_id>
  </id_info>
  <brief_title>Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis</brief_title>
  <official_title>A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Perrigo Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Perrigo Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were to demonstrate comparable safety and efficacy of Ciclopirox
      Olamine Cream (Test Product) and Ciclopirox Cream 0.77% (Reference Product) in the treatment
      of subjects with tinea pedis, and to show the superiority of the active treatments over that
      of the vehicle.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <primary_completion_date type="Actual">May 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects in Each Treatment Group With Therapeutic Success</measure>
    <time_frame>6 weeks</time_frame>
    <description>Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Mycological Cure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Mycological Cure (KOH wet mount negative and fungal culture negative</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Clinical Cure</measure>
    <time_frame>6 weeks</time_frame>
    <description>Clinical Cure was defined as a signs and symptoms score of &lt;1 for erythema; &lt;1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject's current episode of tinea pedis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">561</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ciclopirox Olamine Cream 0.77%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loprox Cream 0.77%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo of test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclopirox Olamine Cream</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loprox Cream 0.77%</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Reference Product</arm_group_label>
    <other_name>Loprox Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>topical cream</description>
    <arm_group_label>Vehicle Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 10 years of age, and otherwise healthy

          -  Clinically and mycologically confirmed diagnosis of symptomatic tinea pedis

          -  In good health with no clinically significant disease that might have interfered with
             study evaluations

          -  Study participant or legal guardian was willing and able to read and sign an IRB
             approved ICF, which included agreement to comply with all study requirements as
             indicated in the protocol. For subjects 10 to 17 years of age, an assent form for
             minors was completed.

        Exclusion Criteria:

          -  History of hypersensitivity or allergy to ciclopirox

          -  Had any skin condition that would interfere with the diagnosis or assessment of tinea
             pedis

          -  Had a history of dermatophyte infecton unresponsive to antifungal treatment

          -  Had a history of alcoholism, drug abuse, or problems that would likely have made the
             subject unreliable for the study

          -  Had any condition or used any medication that, in the opinion of the Investigator,
             might have interfered with the conduct or results of the study or placed the
             prospective subject at increased risk

          -  Was unwilling to sign the informed consent

          -  Female who was pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>May 17, 2012</results_first_submitted>
  <results_first_submitted_qc>May 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 19, 2012</results_first_posted>
  <last_update_submitted>January 17, 2013</last_update_submitted>
  <last_update_submitted_qc>January 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinea Pedis</keyword>
  <keyword>Ciclopirox Olamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclopirox</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Ciclopirox cream</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Loprox Cream</description>
        </group>
        <group group_id="P3">
          <title>Vehicle Product</title>
          <description>placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
                <participants group_id="P2" count="226"/>
                <participants group_id="P3" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="156"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="34"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of fungal pathogen at baseline</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Ciclopirox cream</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Loprox Cream</description>
        </group>
        <group group_id="B3">
          <title>Vehicle Product</title>
          <description>placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="224"/>
            <count group_id="B2" value="226"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="561"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.2" spread="15.6"/>
                    <measurement group_id="B2" value="42.3" spread="15.6"/>
                    <measurement group_id="B3" value="43.1" spread="15.1"/>
                    <measurement group_id="B4" value="43.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects in Each Treatment Group With Therapeutic Success</title>
        <description>Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success</description>
        <time_frame>6 weeks</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ciclopirox Olamine Cream, USP</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Loprox® (ciclopirox) Cream 0.77%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Product</title>
            <description>Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects in Each Treatment Group With Therapeutic Success</title>
          <description>Both Mycological Cure (KOH wet mount negative and fungal culture negative) and Clinical Cure were required to achieve Therapeutic Success</description>
          <population>Per protocol population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>For the primary efficacy analysis, a 90% confidence interval was constructed for the difference in the Therapeutic Success rates between the Test Product and Reference Product at Visit 4/Week 6 (Follow-Up). The interval was calculated using Wald’s method with Yates’ continuity correction. Therapeutic equivalence (bioequivalence) was established if this 90% confidence interval was contained within the interval -0.20 to +0.20 (-0.20% to +0.20%)</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.61</ci_lower_limit>
            <ci_upper_limit>2.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Mycological Cure</title>
        <description>Mycological Cure (KOH wet mount negative and fungal culture negative</description>
        <time_frame>6 weeks</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ciclopirox Olamine Cream, USP</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Loprox® (ciclopirox) Cream 0.77%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Product</title>
            <description>Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Mycological Cure</title>
          <description>Mycological Cure (KOH wet mount negative and fungal culture negative</description>
          <population>per protocol population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Clinical Cure</title>
        <description>Clinical Cure was defined as a signs and symptoms score of &lt;1 for erythema; &lt;1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject’s current episode of tinea pedis</description>
        <time_frame>6 weeks</time_frame>
        <population>per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Ciclopirox Olamine Cream, USP</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Loprox® (ciclopirox) Cream 0.77%</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Product</title>
            <description>Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Clinical Cure</title>
          <description>Clinical Cure was defined as a signs and symptoms score of &lt;1 for erythema; &lt;1 for scaling; and 0 for pruritus, maceration, fissuring/cracking, and burning/stinging; as well as an assessment that no additional antifungal therapy was required to treat the subject’s current episode of tinea pedis</description>
          <population>per protocol population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="166"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Ciclopirox Olamine Cream, USP</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Loprox® (ciclopirox) Cream 0.77%</description>
        </group>
        <group group_id="E3">
          <title>Vehicle Product</title>
          <description>Vehicle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="224"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="226"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Near syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain secondary to head trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="224"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="226"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo Company</organization>
      <phone>718-960-0119</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

